InsiderSignalSign in
← Insider buys

Ansbert Gadicke has bought stock on 3 days since Jan 2021

10% owner at Aktis Oncology, Inc., and 6 other companies

SEC CIK 0001134655 · Filings on SEC.gov ↗

$30.2MBought
$118.6MSold
Jan 14Last buy

Ansbert Gadicke's record

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Companies

Every filing

57 filings since Jan 2021, newest first

AKTSBuy

Aktis Oncology, Inc.

10% owner

$20.0M+12.0%Jan 14
HOWLSell

Werewolf Therapeutics, Inc.

Former 10% Owner

$183K−4.0%Dec 4
HOWLSell

Werewolf Therapeutics, Inc.

10% owner

$137K−3.0%Dec 1
HOWLSell

Werewolf Therapeutics, Inc.

10% owner

$180K−4.0%Nov 25
TCRRSell

Tcr2 Therapeutics Inc.

Director and 10% owner

$132K−1.0%May 24
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$10.5M−5.0%Jan 6
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$4.8M−3.0%Dec 2
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.4M−1.0%Nov 30
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$4.7M−3.0%Nov 24
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$785K−1.0%Oct 18
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.6M−2.0%Oct 14
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.4M−2.0%Oct 12
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.2M−1.0%Oct 5
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$972K−1.0%Sep 30
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.5M−2.0%Sep 27
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$1.6M−1.0%Sep 23
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$103KSep 20
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$4.3M−3.0%Sep 20
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$449KSep 16
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.1M−1.0%Sep 16
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$774KSep 13
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.7M−2.0%Sep 13
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$1.6M−1.0%Sep 8
ITOSSell

Iteos Therapeutics, Inc.

10% owner

$2.1M−1.0%Sep 8
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$816KSep 2
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$1.5M−1.0%Aug 31
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$3.5M−1.0%Aug 25
CGEMSell

Cullinan Oncology, Inc.

Director and 10% owner

$83KAug 12
RPTXSell

Repare Therapeutics Inc.

10% owner

$2.1M−2.0%Jul 13
RPTXSell

Repare Therapeutics Inc.

10% owner

$654KJun 30
RPTXSell

Repare Therapeutics Inc.

10% owner

$961K−1.0%Jun 28
RPTXSell

Repare Therapeutics Inc.

10% owner

$1.5M−1.0%Jun 23
RPTXSell

Repare Therapeutics Inc.

10% owner

$1.4M−1.0%Jun 21
RPTXSell

Repare Therapeutics Inc.

10% owner

$207KJun 16
RPTXSell

Repare Therapeutics Inc.

10% owner

$2.1M−1.0%Jun 10
RPTXSell

Repare Therapeutics Inc.

10% owner

$1.9M−1.0%Jun 7
RPTXSell

Repare Therapeutics Inc.

10% owner

$1.2M−1.0%Jun 2
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$1.2M−1.0%Jun 2
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$347KMay 27
RPTXSell

Repare Therapeutics Inc.

10% owner

$1.3M−1.0%May 27
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$321KMay 24
RPTXSell

Repare Therapeutics Inc.

10% owner

$11.3M−7.0%May 24
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$982K−1.0%May 20
RPTXSell

Repare Therapeutics Inc.

10% owner

$1.6M−1.0%May 20
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$329KMay 17
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$1.4M−1.0%May 12
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$229KMay 6
HOWLBuy

Werewolf Therapeutics, Inc.

10% owner

$3.9M+4.0%May 6
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$7.4M−5.0%May 4
HARPSell

Harpoon Therapeutics, Inc.

10% owner

$2.9M−2.0%Apr 29
Older filings
About Ansbert Gadicke

Ansbert Gadicke, M.D. is a prominent biotech venture capitalist, founder of MPM Capital in 1992, and current Managing Partner of MPM BioImpact (formerly BioImpact Capital).( He has been the lead investor and board member for successful biopharma companies including BioMarin Pharmaceuticals (NASDAQ: BMRN), Idenix (acquired by Merck), Pharmasset (acquired by Gilead, developer of Hepatitis C cure Sovaldi), Mitobridge (acquired by Astellas), Cullinan Oncology (NASDAQ: CGEM), ElevateBio, and Orna Therapeutics, where he serves as Chairman and Co-Founder.(

Gadicke holds an M.D. from J.W. Goethe University in Frankfurt and conducted research at the Whitehead Institute (MIT), Harvard Biochemistry, and the German Cancer Research Center under Nobel Laureate Harald zur Hausen on HPV16/18, with publications in Nature and Cell.( Prior to MPM, he worked at The Boston Consulting Group. He serves on the Harvard Medical School Board of Fellows and Massachusetts General Hospital Research Advisory Council, and received the 2017 Global Oncology Visionary Award. As a 10% Owner and Director, he has engaged in insider trading at companies like Cullinan Oncology and is linked to recent activity at Aktis Oncology, Inc. (AKTS).(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.